Urotensin II and the circulatory system

Hong Kong Journal of Nephrology

Volumn 7, Issue 1, 2005, Pages 9-13

  Ong, Kwok Leung ^a   Cheung, Bernard M Y ^a   Lam, Karen Siu Ling ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hypertension; Renal failure; Urotensin; Vasoactive peptides; Vasoconstriction

Indexed keywords

AMINO ACID; CYCLOPEPTIDE; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; NITRIC OXIDE; RECEPTOR BLOCKING AGENT; UROTENSIN II; VASOCONSTRICTOR AGENT;

CARDIOVASCULAR SYSTEM; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; HEART DISEASE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; NATRIURESIS; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; VASOCONSTRICTION; VASODILATATION;

EID: 18144423519     PISSN: 15615413     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1561-5413(09)60174-5     Document Type: Review

References (40)

1. Bern HA, Pearson D, Larson BA, Nishioka RS. Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Horm Res 1985;41:533-52.
2. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401: 282-6.
3. Onan D, Hannan RD, Thomas WG. Urotensin II: the old kid in town. Trends Endocrinol Metab 2004;15:175-82.
4. Shenouda A, Douglas SA, Ohlstein EH, Giaid A. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 2002;50:885-9.
5. Protopopov A, Kashuba V, Podowski R, Gizatullin R, Sonnhammer E, Wahlestedt C, et al. Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. Cytogenet Cell Genet 2000;88:312-3.
6. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000;131:441-6.
7. Saetrum Opgaard O, Nothacker H, Ehlert FJ, Krause DN. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 2000;406:265-71.
8. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rhokinase. Circ Res 2001;88:1102-4.
9. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 2003;72:1049-60.
10. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001;19: 2185-90.
11. Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003;285:F792-8.
12. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000;130:1865-70.
13. Stirrat A, Gailagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001;280:H925-8.
14. Behm DJ, Doe CP, Johns DG, Maniscalco K, Stankus GP, Wibberley A, et al. Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:274-80.
15. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002;135:25-7.
16. Wilkinson IB, Affolter JT, de Haas SL, Pelligrini MP, Boyd J, Winter MJ, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002;53:341-7.
17. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002;54:617-21.
18. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 2001;132: 5-9.
19. Affolter J, Webb DJ. Urotensin II: a new mediator in cardiopulmonary regulation? Lancet 2001;358:774-5.
20. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, et al. Role of urotensin II in patients on dialysis. Lancet 2001;358: 810-1.
21. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 2002;360:545-6.
22. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003; 285:H1576-81.
23. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 2003;104:1-5.
24. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002;37:767-72.
25. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J. Inhibition of insulin release by urotensin II - a study on the perfused rat pancreas. Horm Metab Res 2001;33:379-81.
26. Zhu F, Ji L, Luo B. The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population. Zhonghua Yi Xue Za Zhi 2002;82:1473-5. [In Chinese]
27. Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, et al. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003;46: 972-6.
28. Thompson JP, Watt P, Sanghavi S, Strupish JW, Lambert DG. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg 2003;97:1501-3.
29. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004;22: 1341-4.
30. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001;104:16-8.
31. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001;19:2191-6.
32. Zuo HH, Hong JM, Guo HS, Wei JR, He YH, Li ZL. Urotensin II induces hypertrophy of in vitro cultured neonatal rat cardiac myocytes. Di Yi Jun Yi Da Xue Xue Bao 2004;24:642-5. [In Chinese]
33. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 2004;18:2344-54.
34. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002;359:1990-7.
35. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002;106:2877-80.
36. Lapp H, Boerrigter G, Costello-Boerrigter LC, Jaekel K, Scheffold T, Krakau I, et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy, Int J Cardiol 2004; 94:93-7.
37. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004; 109:1212-4.
38. He YH, Hong JM, Guo HS, Wei JR, Chen H, Zuo HH, et al. Effects of urotensin II on cultured cardiac fibroblast proliferation and collagen type I mRNA expression. Di Yi Jun Yi Da Xue Xue Bao 2004;24:505-8. [In Chinese]
39. Zhang Y, Li J, Cao J, Chen J, Yang J, Zhang Z, et al. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 2002;16:64-8.
40. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy, Circ Res 2003;93: 246-53.